IL-17A and IFN-γ synergistically induce RNase 7 expression via STAT3 in primary keratinocytes

PLoS One. 2013;8(3):e59531. doi: 10.1371/journal.pone.0059531. Epub 2013 Mar 21.

Abstract

Human keratinocytes produce several antimicrobial peptides and proteins (AMP) which contribute to the protection of human skin against infection. RNase 7 is a major AMP involved in cutaneous defense with a high expression in keratinocytes and a broad spectrum of antimicrobial activity. The cytokine IL-17A has been recently identified as a potent inducer of several AMP in keratinocytes. Since the role of IL-17A to induce RNase 7 expression is unknown we analyzed IL-17A alone and in combination with other cytokines to induce RNase 7 expression in keratinocytes. Whereas IL-17A alone only weakly induced RNase 7 expression, the synergistic combination of IL-17A and IFN-γ (IL-17A/IFN-γ) was identified as a potent inducer of RNase 7 expression. This combination was more effective in inducing RNase 7 than the combination of IL-17A/TNF-α, a combination previously identified as a strong inducer of psoriasis-related immune response genes including several AMP. IFN-γ and IL-17A both have been reported to activate the transcription factor STAT3 (Signal transducer and activator of transcription 3). Therefore we investigated the influence of STAT3 on the IL-17A/IFN-γ -mediated RNase 7 induction. The use of a STAT3 inhibitor as well as siRNA-mediated downregulation of STAT3 resulted in a diminished IL-17A/IFN-γ -mediated RNase 7 induction in keratinocytes indicating that STAT3 is involved in this process. Similarly as seen with RNase 7, treatment of keratinocytes with IL-17A/IFN-γ revealed also a synergistic induction of gene expression of the AMP human beta-defensin (hBD)-2 and -3 as well as the S100 protein psoriasin (S100A7) indicating that the combination of IL-17A/IFN-γ is a potent inducer of various AMP classes in general. This was also reflected by an increase of the Staphylococcus aureus-killing activity of IL-17A/IFN-γ -treated keratinocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Gene Expression Regulation, Enzymologic / drug effects*
  • Humans
  • Interferon-gamma / pharmacology*
  • Interleukin-17 / pharmacology*
  • Keratinocytes / drug effects*
  • Keratinocytes / metabolism*
  • Keratinocytes / microbiology
  • Ribonucleases / genetics
  • Ribonucleases / metabolism*
  • S100 Calcium Binding Protein A7
  • S100 Proteins / genetics
  • STAT3 Transcription Factor / metabolism*
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / physiology
  • beta-Defensins / genetics

Substances

  • DEFB103A protein, human
  • DEFB4A protein, human
  • Interleukin-17
  • S100 Calcium Binding Protein A7
  • S100 Proteins
  • S100A7 protein, human
  • STAT3 Transcription Factor
  • beta-Defensins
  • Interferon-gamma
  • Ribonucleases
  • Ribonuclease 7

Grants and funding

This study was supported by Deutsche Forschungsgemeinschaft (HA 3386/6-1), a grant of the Federal Ministry of Education and Research (BMBF, SkinStaph) given to R. Gläser and J. Harder and a Heisenberg program of the Deutsche Forschungsgemeinschaft given to J. Harder. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.